WO2006102979A3 - Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen - Google Patents

Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen Download PDF

Info

Publication number
WO2006102979A3
WO2006102979A3 PCT/EP2006/002230 EP2006002230W WO2006102979A3 WO 2006102979 A3 WO2006102979 A3 WO 2006102979A3 EP 2006002230 W EP2006002230 W EP 2006002230W WO 2006102979 A3 WO2006102979 A3 WO 2006102979A3
Authority
WO
WIPO (PCT)
Prior art keywords
markers
cardiovascular diseases
combinations
inflammation
biochemical
Prior art date
Application number
PCT/EP2006/002230
Other languages
English (en)
French (fr)
Other versions
WO2006102979A2 (de
Inventor
Stefan Blankenberg
Hans J Rupprecht
Christoph Bickel
Original Assignee
Univ Mainz Johannes Gutenberg
Stefan Blankenberg
Hans J Rupprecht
Christoph Bickel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200510014752 external-priority patent/DE102005014752A1/de
Application filed by Univ Mainz Johannes Gutenberg, Stefan Blankenberg, Hans J Rupprecht, Christoph Bickel filed Critical Univ Mainz Johannes Gutenberg
Publication of WO2006102979A2 publication Critical patent/WO2006102979A2/de
Publication of WO2006102979A3 publication Critical patent/WO2006102979A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft neue Marker der vaskulären Entzündung und Kombinationen davon als Werkzeuge zur Diagnose und deren Prognose in Patienten mit kardiovaskulären Erkrankungen. Die Marker dienen weiterhin als Werkzeuge, die die Auswahl von Wirkstoffen zur Behandlung solcher Erkrankungen erleichtern und schließlich als Ansatzpunkt für die Behandlung von kardiovaskulären Erkrankungen. Weiterhin betrifft die Erfindung die Erstellung eines individuellen Risikoprofils von negativen Vorgängen, die mit dem Fortschreiten der Arteriosklerose zusammenhängen.
PCT/EP2006/002230 2005-03-31 2006-03-10 Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen WO2006102979A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66694805P 2005-03-31 2005-03-31
DE200510014752 DE102005014752A1 (de) 2005-03-31 2005-03-31 Entzündungsmarker und Kombinationen davon als biochemische Marker bei kardiovaskulären Erkrankungen
DE102005014752.6 2005-03-31
US60/666,948 2005-03-31

Publications (2)

Publication Number Publication Date
WO2006102979A2 WO2006102979A2 (de) 2006-10-05
WO2006102979A3 true WO2006102979A3 (de) 2007-04-26

Family

ID=36579585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/002230 WO2006102979A2 (de) 2005-03-31 2006-03-10 Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen

Country Status (1)

Country Link
WO (1) WO2006102979A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147115A4 (de) * 2007-04-16 2010-05-05 Kardiobioindex/kardiobioscore und verwendung des speichelproteoms in der kardiovaskulären diagnostik
WO2010018870A1 (ja) 2008-08-15 2010-02-18 藤倉化成株式会社 動脈硬化診断用ポリペプチドマーカー、及び該マーカー等を用いる動脈硬化の検出方法、並びに動脈硬化診断用キット
WO2011025917A1 (en) * 2009-08-28 2011-03-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102175873A (zh) * 2011-01-11 2011-09-07 江苏迈迪基因生物科技有限公司 心脑血管疾病蛋白标志物的联合并行检测方法及其诊断试剂盒
CN102680697B (zh) * 2011-03-10 2015-11-25 王迎峰 检测肌钙蛋白i的试剂盒及其制备和使用方法
CN110763839A (zh) * 2019-10-31 2020-02-07 安徽大千生物工程有限公司 一种timp-i胶乳增强比浊法检测试剂盒及其制备使用方法
WO2024037387A1 (en) * 2022-08-19 2024-02-22 Tianjin Yunjian Medical Technology Co., Ltd. Blood biomarkers and methods for diagnosis of acute kawasaki disease

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANKERSMIT, H.J., ET AL: "Increased serum concentrations of soluble CD95/Fas and caspase 1/ICE in patients with acute angina", HEART, vol. 90, 2004, pages 151 - 154, XP002416906 *
BENJAFIELD, A.V., ET AL: "Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease", JOURNAL OF MOLECULAR MEDICINE, vol. 79, 2001, pages 109 - 115, XP002416905 *
BICKEL, C., ET AL: "Relation of Markers of Inflammation (C-Reactive Protein, Fibrinogen, von Willebrand Factor, and Leukocyte Count) and Statin Therapy to Long-Term Mortality in Patients With Angiographically Proven Coronary Artery Disease", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 89, 15 April 2002 (2002-04-15), pages 901 - 908, XP002316705 *
BLANKENBERG, S., ET AL: "Haplotypes of the Caspase-1 Gene, Plasma Caspase-1 Levels and Cardiovascular Risk", CIRCULATION RESEARCH, vol. 99, no. 1, 2006, XP002416907 *
ECONOMOU, E., ET AL: "Serum levels of interleukin-1beta converting enzyme/caspase-1 can be used to detect and quantify apoptotic process in patients with coronary artery disease undergoing percutaneous transluminal coronary angioplasty", EUROPEAN HEART JOURNAL, ABSTRACT SUPPLEMENT, vol. 21, 2000, pages 158, XP009077827 *
LYUTOVA L V ET AL: "53. High fibrinogen level as an early criterion of the cardio-vascular disease (CVD)", FIBRINOLYSIS, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 10, May 1996 (1996-05-01), pages 16 - 17, XP004920960, ISSN: 0268-9499 *
MA, J., ET AL: "A Prospective Study of Fibrinogen and Risk of Myocardial Infarction in the Physicians' Health Study", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 33, no. 5, 1999, pages 1347 - 1352, XP002386351 *
PANAGIOTAKOS D B ET AL: "The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA Study", PREVENTIVE MEDICINE, ACADEMIC PRESS, XX, vol. 40, no. 4, 25 August 2004 (2004-08-25), Online, pages 432 - 437, XP004626943, ISSN: 0091-7435 *
PORSCH-OEZCUERUEMEZ, M., ET AL: "Evaluation of Serum Levels of Solubilized Adhesion Molecules and Cytokine Receptors in Coronary Heart Disease", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 34, no. 7, 1999, pages 1995 - 2001, XP002416904 *
ROSSI, M. L., ET AL: "Different Quantitative Apoptotic Traits in Coronary Atherosclerotic Plaques From Patients With Stable Angina Pectoris and Acute Coronary Syndromes", CIRCULATION, vol. 110, 2004, pages 1767 - 1773, XP002416903 *
SARASTE, A., ET AL: "Soluble tumor necrosis factor receptor levels identify a subgroup of heart failure patients with increased cardiomyocyte apoptosis", CLINICA CHIMICA ACTA, vol. 320, 2002, pages 65 - 67, XP002416902 *
TZIAKAS, D., ET AL: "Prolonged activation of Tumor necrosis factor (TNF)-a and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3", EUROPEAN CYTOKINE NETWORK, vol. 15, no. 3, September 2004 (2004-09-01), pages 231 - 239, XP002416901 *

Also Published As

Publication number Publication date
WO2006102979A2 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2004046722A3 (de) Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006102979A3 (de) Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen
EP1859793A4 (de) Neue kombinierte anwendung einer sulfonamid-verbindung
WO2005077093A3 (en) Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2007007173A3 (en) Human anti-madcam antibodies
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2005075665A3 (en) Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
WO2005113752A3 (en) Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
WO2006003492A3 (en) Compositions and methods for treating pathological infections
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
WO2007012057A3 (en) Vegetation water composition for treatment of inflammatory skin conditions
WO2004071382A3 (en) Substituted heterocycles
WO2006034512A3 (en) Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
WO2006128041A3 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2006050826A3 (de) Behandlung von mastitis mit enrofloxacin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06723344

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6723344

Country of ref document: EP